United Therapeutics Corporation Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax
United Therapeutics Corporation (UTHR) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax · last filed 2026-02-25
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, prior service cost (credit), after reclassification adjustment, before tax for fiscal 2025 was $0.00.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, prior service cost (credit), after reclassification adjustment, before tax for fiscal 2024 was -$200.00K.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, prior service cost (credit), after reclassification adjustment, before tax for fiscal 2023 was -$400.00K.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, prior service cost (credit), after reclassification adjustment, before tax for fiscal 2022 was -$700.00K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2024-12-31 | -$200.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | -$400.00K 10-K · filed 2026-02-25 |
| 2022-12-31 | -$700.00K 10-K · filed 2025-02-26 |
| 2021-12-31 | -$700.00K 10-K · filed 2024-02-21 |
| 2020-12-31 | -$1.30M 10-K · filed 2023-02-22 |
| 2019-12-31 | -$1.50M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |